Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni RA Razak(University Health Network), Kyriakos P. Papadopoulos(Texas Oncology), Víctor Moreno, William J. Edenfield(Prisma Health), James M. Cleary(Brigham and Women's Hospital), Annemie Rutten(GZA Ziekenhuizen Campus Sint-Augustinus), R. Donald Harvey(Emory University), David P. Ryan(East Carolina University), Hansen Wong(Amgen (United States)), Dirk Nagorsen(Amgen (United States)), Jeanne Tie(The Royal Melbourne Hospital), Anthony J. Olszanski(Fox Chase Cancer Center), Michael Boyer(Chris O’Brien Lifehouse), Manish A. Shah(NewYork–Presbyterian Hospital), Gloria Juan(Amgen (United States)), Neelesh Soman(Amgen (United States)), Marie-Anne Damiette Smit(Amgen (United States)), Erik Rasmussen(Amgen (United States)), Dirk Jäger(Memorial Sloan Kettering Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 117
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k